Cognition Therapeutics (CGTX) Total Current Liabilities (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Total Current Liabilities of $6.1 million for Q1 2026, down 44.72% year-over-year from $11.0 million in Q1 2025, and down 56.53% quarter-over-quarter from $13.9 million in Q4 2025.
Cognition Therapeutics (CGTX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Total Current Liabilities for 7 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 44.72% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 44.72% YoY), while the FY2025 annual figure was $13.9 million, up 24.97% from the prior year.
- Total Current Liabilities eased to $6.1 million in Q1 2026 per CGTX's latest filing, from $13.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $13.9 million in Q4 2025 and bottomed at $6.1 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $9.6 million across 5 years, with a median of $9.5 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 173.62% — and 2025, when it sank 47.63%.
- Cognition Therapeutics' Total Current Liabilities stood at $7.8 million in 2022, then surged by 30.46% to $10.2 million in 2023, then grew by 9.57% to $11.1 million in 2024, then grew by 24.97% to $13.9 million in 2025, then tumbled by 56.53% to $6.1 million in 2026.
- Business Quant data shows CGTX's Total Current Liabilities at $6.1 million in Q1 2026, $13.9 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.45 Mn |
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 13.92 Mn |
| Sep 30, 2025 | 6.65 Mn |
| Jun 30, 2025 | 12.36 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 12.71 Mn |
| Jun 30, 2024 | 10.92 Mn |
| Mar 31, 2024 | 9.50 Mn |
| Dec 31, 2023 | 10.17 Mn |
| Sep 30, 2023 | 8.23 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 7.47 Mn |
| Dec 31, 2022 | 7.80 Mn |
| Sep 30, 2022 | 12.12 Mn |
| Jun 30, 2022 | 6.82 Mn |
| Mar 31, 2022 | 7.65 Mn |
| Dec 31, 2021 | 7.86 Mn |
| Sep 30, 2021 | 4.43 Mn |